Tempus expands strategic collaboration with Bristol Myers Squibb
TEM•Tempus AI expanded its collaboration with Bristol Myers Squibb, which will license Tempus’s multimodal oncology data through 2031 and gain access to its LENS platform for oncology drug development.
1. Expanded collaboration
Bristol Myers Squibb will license multimodal oncology data from Tempus through 2031 to support the identification of biological and clinical insights. It will also gain access to Tempus’s LENS platform, described as an AI-first, agentic platform for oncology drug development.
